CD8A and neoplasm: Together with the significant increase in tumor-infiltrating CD3+CD8+ and CD3+CD4+ T effectors, this resulted in enhanced CD4+Teff/Treg and CD8+/Treg ratios in MTR-OralGem-treated mice (Figure 6F,G).